Direct-acting antiviral (DAA) exposure may not be associated with higher rates of any serious adverse events when used for hepatitis C virus (HCV) treatment, according to a study published in JAMA Network Open. At this time, there are approximately 2.4 million individuals living in the United States who are infected with HCV. Further, 28% of…
Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
Investigators sought to determine the risk for Parkinson disease development in patients with hepatitis C virus who received antiviral treatment and in patients who did not receive this treatment.
Advantage of interferon-based antiviral therapy reached statistical significance at five-year follow-up
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
The impact of direct-acting antiviral therapy was investigated in a large cohort of patients in complete remission following treatment of hepatitis C-related HCC.
Findings suggest that states should consider revising their HCV treatment policies to include all individuals infected with HCV to achieve significant patient- and population-level benefits.
Data suggests that prevention strategies and frequent testing with HCV-RNA should be applied after sustained virologic response in MSM who engage in high-risk practices.
Investigators evaluated the real-life efficacy of pegylated interferon α-2b with ribavirin in treatment-naive patients with chronic genotypes 2 or 3 hepatitis C virus infection.
